125 related articles for article (PubMed ID: 36748817)
1. Characterization of Dicaffeoylspermidine Derivatives from Wolfberry as Potent and Selective Inhibitors of Human Cytochrome P450 46A1
Du J; Liu J; Wang S; Wang C; Meng Q; Sun H; Liu K; Liu Y; Wu J
Curr Drug Metab; 2023; 24(2):124-130. PubMed ID: 36748817
[TBL] [Abstract][Full Text] [Related]
2.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
4. Molecular Basis of the Recognition of Cholesterol by Cytochrome P450 46A1 along the Major Access Tunnel.
Shi N; Zheng Q; Zhang H
ACS Chem Neurosci; 2022 May; 13(10):1526-1533. PubMed ID: 35438962
[TBL] [Abstract][Full Text] [Related]
5. Lycibarbarspermidines A-O, New Dicaffeoylspermidine Derivatives from Wolfberry, with Activities against Alzheimer's Disease and Oxidation.
Zhou ZQ; Fan HX; He RR; Xiao J; Tsoi B; Lan KH; Kurihara H; So KF; Yao XS; Gao H
J Agric Food Chem; 2016 Mar; 64(11):2223-37. PubMed ID: 26953624
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
Mast N; White MA; Bjorkhem I; Johnson EF; Stout CD; Pikuleva IA
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9546-51. PubMed ID: 18621681
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
8. Characterization of three naturally occurring lignans, sesamol, sesamolin, and sesamin, as potent inhibitors of human cytochrome P450 46A1: Implications for treating excitatory neurotoxicity.
Du J; Chen X; Zhao Y; Zhao T; Wang D; Chen Z; Wang C; Meng Q; Yao J; Sun H; Liu K; Wu J
Front Pharmacol; 2022; 13():1046814. PubMed ID: 36483743
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Glycyrrhiza Polysaccharide on Human Cytochrome P450 46A1 in vitro and in vivo: Implications in Treating Neurological Diseases.
Du J; Chen Z; Chen X; Zhang J; Wang Y; Zhao T; Wang D; Wang C; Chen Y; Meng Q; Sun H; Liu K; Wu J
Curr Drug Metab; 2024 May; ():. PubMed ID: 38797896
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1.
Putkaradze N; Hartz P; Hutter MC; Zapp J; Thevis M; Bernhardt R
J Steroid Biochem Mol Biol; 2021 Sep; 212():105927. PubMed ID: 34089835
[TBL] [Abstract][Full Text] [Related]
13. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
Mast N; Charvet C; Pikuleva IA; Stout CD
J Biol Chem; 2010 Oct; 285(41):31783-95. PubMed ID: 20667828
[TBL] [Abstract][Full Text] [Related]
15. The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro.
Mast N; Fotinich A; Pikuleva IA
Drug Metab Dispos; 2022 Jul; 50(7):923-930. PubMed ID: 35489779
[TBL] [Abstract][Full Text] [Related]
16. Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal.
Saadane A; Mast N; Trichonas G; Chakraborty D; Hammer S; Busik JV; Grant MB; Pikuleva IA
Am J Pathol; 2019 Feb; 189(2):405-425. PubMed ID: 30448403
[TBL] [Abstract][Full Text] [Related]
17. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
18. Transcription of cytochrome P450 46A1 in NIH3T3 cells is negatively regulated by FBS.
Shinohara Y; Ando H; Maekawa M; Arai M; Horibata Y; Satou M; Jojima T; Usui I; Aso Y; Sugimoto H
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jun; 1867(6):159136. PubMed ID: 35306146
[TBL] [Abstract][Full Text] [Related]
19. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive and selective detection of cytochrome P450 46A1 activity by a ultra-high-performance liquid chromatography-tandem mass spectrometry method.
Wang S; Wang X; Wang Z; Wang Z; Jiang L; Liu J; Wu J; Liu Y
Biomed Chromatogr; 2022 Mar; 36(3):e5291. PubMed ID: 34854105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
